Snapshot from Aug 13, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / VERAXA advances VXA-222 with OmniAb
Business pipeline milestone

VERAXA advances VXA-222 with OmniAb

Analysis based on 6 articles · First reported Jul 27, 2026 · Last updated Jul 27, 2026

Sentiment
20
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The advancement of VXA-222 is a positive signal for VERAXA's pipeline progress, potentially boosting investor confidence in its ADC platform. For OmniAb, Inc., the milestone validates its discovery technology and may lead to future revenue from the collaboration.

biotechnology pharmaceuticals
Event Summary

VERAXA Biotech AG AG (Nasdaq: VRXA) announced the advancement of its bispecific antibody-drug conjugate (bsADC) program VXA-222 after achieving a key technical milestone in its collaboration with OmniAb, Inc., Inc. (Nasdaq: OABI). OmniAb, Inc. successfully completed its discovery work, allowing the program to move into its next phase. VXA-222 uses an 'AND-gate' logic to target two tumor antigens on solid tumors. The collaboration, established in May 2025, combines OmniAb, Inc.'s antibody discovery technologies, including the OmniClic platform, with VERAXA's proprietary linker and conjugation expertise. VERAXA holds exclusive rights to develop and commercialize products from the collaboration, with OmniAb, Inc. entitled to a share of specified revenue.

Key Actions
80 VERAXA Biotech AG advanced
70 OmniAb, Inc. completed
Entities Involved
priv
VERAXA Biotech AG
VERAXA is the lead developer of VXA-222; the milestone advances its pipeline and strengthens its position in bispecific ADCs.
Importance 100.0 Sentiment 30.0
priv
OmniAb, Inc.
OmniAb, Inc.'s discovery work enabled the milestone; it is entitled to revenue share from resulting products.
Importance 80.0 Sentiment 20.0
per
Christoph Erkel
As CSO of VERAXA, he commented on the achievement, highlighting the partnership's success.
Importance 30.0 Sentiment 0.0
per
W. Averell Harriman
As SVP at OmniAb, Inc., he expressed satisfaction with the collaboration's progress.
Importance 20.0 Sentiment 0.0
exch
Nasdaq
Both VERAXA and OmniAb, Inc. are listed on Nasdaq; the event may influence their stock prices.
Importance 5.0 Sentiment 0.0
ngo
European Molecular Biology Laboratory
VERAXA was founded on scientific breakthroughs from EMBL, but EMBL is not directly involved in this event.
Importance 5.0 Sentiment 0.0
Relationships
VERAXA Biotech AG related ↔ Christoph Erkel
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.